NSE: GLAND | BSE: 543245

Mid-range Performer

Download real time

1902.50 -18.50 (-0.96%)

48.89% Gain from 52W Low

136.3K NSE+BSE Volume

NSE 10 Sep, 2025 3:31 PM (IST)

31,344.9

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Gland Pharma Ltd.

09 Nov 2020, 08:40AM

1902.50

-0.96%

Gland Pharma Ltd - IPO Note 09112020

IPO Note: Gland Pharma Ltd.

HDFC Securities

Gland Pharma Ltd - IPO Note Issue Open: Nov 09 Nov 11, 2020 Price Band: Rs. 1490 1500 *Issue Size: 43,196,968 eq shares (Fresh Issue of 8,333,333 eq sh + Offer for sale of 34,863,635 eq sh) Issue Size: Rs. 6436.3 6479.5 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh Face Value: Rs 1 Book value: Rs 255.79 (June 30, 2020) Bid size: - 10 equity shares and in multiples thereof 100% Book built Issue Capital Structure: Pre Issue Equity: Rs. 15.49 cr Post issue Equity: Rs. 16.33 cr Listing: BSE & NSE

Gland Pharma Ltd. has an average target of 2145.00 from 2 brokers.

Gland Pharma Ltd.

09 Nov 2020, 12:00AM

1902.50

-0.96%

Gland Pharma Ltd. IPO Note

IPO Note: Gland Pharma Ltd.

Ashika Research

The Company will not receive any proceeds of the Offer for Sale by the Selling Shareholder. (up to 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd, up to 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Ltd, up to 3,573,014 equity shares by Empower Discretionary Trust and up to 1,874,500...

Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.

Gland Pharma Ltd.

09 Nov 2020, 12:00AM

1902.50

-0.96%

Gland Pharma IPO

IPO Note: Gland Pharma Ltd.

ICICI Securities Limited

Established in Hyderabad in 1978, Gland Pharma is one of the largest and fastest growing injectable-focused B2B companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets. It is a niche player in sterile injectables, oncology and ophthalmic solutions with focus on first-to-file, 505(b)(2) filings and NCE- 1s. Along with its partners Gland has 267 ANDA filings (101 owned) in the US as of Q1FY21, of which 215 were approved. The company has seven manufacturing facilities in India, comprising four formulations facilities with...

Gland Pharma Ltd. is trading above its 200 day SMA of 1693.2

Gland Pharma Ltd.

08 Nov 2020

1902.50

-0.96%

GLAND PHARMA LTD

IPO Note: Gland Pharma Ltd.

Ventura

IPO NOTE

Gland Pharma Ltd. is trading above its 200 day SMA of 1693.2

Gland Pharma Ltd.

27 Jul 2020

1902.50

-0.96%

Gland Pharma

IPO Note: Gland Pharma Ltd.

Angel Broking

Gland Pharma is one of the fastest growing generic injectable-focused companies by revenue in the United States from 2014 to 2019 as per IQVIA report. Company sells its products primarily under a B2B model which accounted for 97% of FY2020 revenues. Company exports to over 60 countries as of June 30, 2020, including the United

Gland Pharma Ltd. is trading below its 30 day SMA of 1942.8

VOTE: Is Gland Pharma Ltd. worth buying?

215 Votes:

Buy 80.93%

Sell 9.3%

Hold 9.77%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf